Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sparano

Showing results (491-500 of 560) with videos related to

Pageof 56
Sort By:
Investigational New Drugs|February 15, 2014
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomachAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 9, 2018
Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trialK Kalinsky, J A Sparano, X Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2023
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast CancerDavid W Cescon, John Hilton, Serafin Morales Murilo, et al.
Science Immunology|September 29, 2023
NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosisSonja Marinović, Maja Lenartić, Karlo Mladenić, et al.
Journal for Immunotherapy of Cancer|July 9, 2025
Gene-expression signature predicts autoimmune toxicity in metastatic melanomaDomenico Mallardo, Mario Fordellone, Michael Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)Seema A Khan, Fengmin Zhao, Lori J Goldstein, et al.
JCO Precision Oncology|September 11, 2020
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple CancersScooter Willis, Yuliang Sun, Mark Abramovitz, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.
Pageof 56

Showing results (491-500 of 560) with videos related to

Sort By:
Pageof 56
Investigational New Drugs|February 15, 2014
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomachAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 9, 2018
Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trialK Kalinsky, J A Sparano, X Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2023
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast CancerDavid W Cescon, John Hilton, Serafin Morales Murilo, et al.
Science Immunology|September 29, 2023
NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosisSonja Marinović, Maja Lenartić, Karlo Mladenić, et al.
Journal for Immunotherapy of Cancer|July 9, 2025
Gene-expression signature predicts autoimmune toxicity in metastatic melanomaDomenico Mallardo, Mario Fordellone, Michael Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)Seema A Khan, Fengmin Zhao, Lori J Goldstein, et al.
JCO Precision Oncology|September 11, 2020
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple CancersScooter Willis, Yuliang Sun, Mark Abramovitz, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.
Pageof 56